Delving into the Latest Updates on E-CEL UVEC with Synapse

Overview

Basic Info

Drug Type

Gene therapy, Stem cell therapy

Synonyms-

Target-

Mechanism

Cell replacements

Therapeutic Areas

Nervous System DiseasesDigestive System DisordersOther Diseases

Active Indication

Fissure in AnoFistulaMuscular Atrophy+ [2]

Inactive Indication-

Originator Organization

Angiocrine Bioscience, Inc.

Active Organization

Angiocrine Bioscience, Inc.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

This clinical trial is being conducted by investigators who are colorectal surgeons. Eligible study participants will receive the experimental treatment E-CEL UVEC cells by direct injection into the anal fissure. The study is being conducted to determine if E-CEL UVEC cell injections will be safe and would have any effects on healing of the anal fissure.

Start Date01 Sep 2024

Sponsor / Collaborator

Weill Medical College of Cornell University

[+1]

NCT04190862 / RecruitingPhase 1IIT

An Open-Label, Single-Center, Investigator Initiated Phase 1B Trial of E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas

The purpose of this study is to determine if endothelial cells derived from human umbilical vein are safe for use in conjunction with fistulotomy for the treatment of simple anal fistulas. Endothelial cells are a special kind of cell in the body that line the inside surface of blood vessels. The goal of the study is to evaluate the preliminary safety of human umbilical vein cells in anal fistula healing.

Start Date22 Jan 2020

Sponsor / Collaborator

Weill Medical College of Cornell University

[+1]

NCT04057833 / Active, not recruitingPhase 1IIT

A Phase 1 Open-Label, Single-Center Investigator Initiated Trial (IIT) of E-CEL UVEC Cells as an Adjunct Cell Therapy for the Arthroscopic Rotator Cuff Repair in Adults

This is a phase 1b investigator-initiated clinical trial that will evaluate the safety and feasibility of E-CEL UVEC® cells with the aim of improving outcomes for patients with full-thickness rotator cuff tears who undergo arthroscopic surgical repair.
Allogeneic E-CEL UVEC cells will be delivered to the tendon repair site and to the muscle adjacent to the tendon repair site.

Start Date20 Nov 2019

Sponsor / Collaborator

Hospital for Special Surgery

[+1]

100 Clinical Results associated with E-CEL UVEC

Login to view more data

100 Translational Medicine associated with E-CEL UVEC

Login to view more data

100 Patents (Medical) associated with E-CEL UVEC

Login to view more data

100 Deals associated with E-CEL UVEC

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Fissure in Ano	Phase 1	US	Angiocrine Bioscience, Inc.	01 Sep 2024
Fistula	Phase 1	US	Angiocrine Bioscience, Inc.	22 Jan 2020
Muscular Atrophy	Phase 1	US	Angiocrine Bioscience, Inc.	20 Nov 2019
Rotator Cuff Tendinitis	Phase 1	US	Angiocrine Bioscience, Inc.	20 Nov 2019
Rupture	Phase 1	US	Angiocrine Bioscience, Inc.	20 Nov 2019